Request Your Free White Paper Now:

"Optimizing Tech Transfer for Radiopharma: A Development-First Model Built for Scale"

Download this whitepaper to learn more.

Radiopharmaceuticals have emerged as a cornerstone of precision medicine, but scaling their production requires navigating a complex and highly specialized manufacturing process. A radiopharma program’s success hinges on a smooth tech transfer to a capable CDMO—a process often fraught with delays, mismatches, and costly setbacks. This whitepaper explores how Nucleus RadioPharma reduces this risk through a purpose-built development and production model:

Step 1: Transfer into a dedicated development lab to assess and refine methods.
Step 2: Move to cGMP for engineering batches and formal validation.

The result is faster, more predictable transitions that keep programs on track for clinical milestones and regulatory submissions. By adapting a pharma-grade model to the scale and complexity of radiopharma, Nucleus helps early-stage innovators move quickly and safely from lab to cGMP—and deliver treatments to patients sooner.

Offered Free by: Nucleus RadioPharma
See All Resources from: Nucleus RadioPharma